Executive Summary

Valued at 159.3 USD Billion in 2025, the Pharmaceutical Packaging Market is forecast to reach 367.9 USD Billion by 2035, expanding at a CAGR of 8.73%.

Growth is anchored in two mechanisms: expanding injectable and biologic drug volumes that require validated primary containment, and serialization mandates under the U.S. Drug Supply Chain Security Act that push labeling and traceability spend onto every pack. Contract manufacturers are absorbing much of this compliance burden on behalf of drug producers.

North America held 39.0% of the market in 2025, supported by a concentrated pharmaceutical manufacturing base and major drugmaker presence. Asia Pacific is the fastest-growing region through 2035, tied to expanding healthcare infrastructure across China and India. Primary packaging – blister packs, vials, bottles and prefilled syringes – led with a 77% share.

The principal constraint is the cost and lead time of requalifying primary packaging materials under FDA and EMA validation protocols whenever a drug product changes container or closure. Competition remains moderately consolidated, with converters differentiating on regulatory qualification status, barrier performance and serialization-ready line capability rather than price alone.

Key Takeaways

• The Pharmaceutical Packaging Market was valued at USD 159.29 Billion in 2025, projected to reach USD 367.88 Billion by 2035 at a CAGR of 8.73%.
• Primary packaging led with a 77% share in 2025, the direct drug-contact barrier across blister packs, vials, and prefilled syringes.
• Secondary packaging is the fastest-growing product segment, driven by carton and label demand tied to serialization rules.
• North America held a 39.0% share in 2025, anchored by its pharmaceutical manufacturing base.
• Serialization mandates such as the US DSCSA are pushing carton and label reformulation.
• Resin and pulp price volatility remains the principal restraint on converter margins.

Market Definition and Scope

The Pharmaceutical Packaging Market spans primary, secondary, and tertiary formats that contain, protect, and label drug products from the filler through distribution. Its boundary covers substrates – plastics and polymers, glass, paper and paperboard, and aluminum foil – converted into blister packs, vials, ampoules, prefilled syringes, bottles, cartons, and labels, valued for barrier properties and dosage containment, alongside contract packaging services such as bottling, labeling, and serialization performed for pharmaceutical manufacturers, retail pharmacies, and institutional pharmacies.

Excluded are active pharmaceutical ingredient production, drug formulation, and manufacturing equipment, and non-drug medical device packaging, which fall under separate market categories. General food, beverage, and consumer-goods packaging using the same substrates sits outside the boundary, as does packaging machinery and capital equipment used at converter and filler sites.

Market Trends

Nitrosamine-Mitigation Materials Are Moving Compliance from Formulation to the Pack

Aptar Active Material Science’s N-Sorb technology, accepted into the US FDA’s Emerging Technology Program in August 2024 and granted a USPTO allowance on 9 June 2026, mitigates nitrosamine risk through the packaging material itself rather than a drug reformulation. It is designed to apply in blister packs, bottle systems and film-based structures without a process change. The shift follows tightened FDA scrutiny of nitrosamine impurities in oral solid-dose products, which had previously forced costly reformulation and requalification cycles. Generic and branded solid-dose manufacturers, along with blister and bottle converters, are the direct adopters. Over the forecast period, this repositions active-material packaging from a niche barrier function into a standard regulatory-compliance line item, adding a new specification layer to routine pack sourcing decisions.

Mono-Material Blister Structures Are Reaching Barrier Parity with PVC/Aluminium Laminates

Bayer’s mono-material PET blister for Aleve, developed with Liveo Research, cuts per-unit carbon emissions by 38%, water use by 78% and land use by 53% against the incumbent PVC/aluminium structure, with a related mono-PET blister tray certified recyclable by Petcore in December 2024. Design-for-recycling mandates are pushing converters to prove recyclability against a named scheme rather than assert it generically. OTC and consumer-health brand owners, together with blister converters serving them, are first movers because reformulation risk is lower than for prescription products. As qualification cost falls and barrier performance closes the gap with mono-PVC, mono-material adoption is set to widen from blister trays into broader rigid pharma formats through the forecast period.

Biologics Manufacturing Is Pulling Demand Toward Sterile Ready-to-Use Containment

SCHOTT Pharma’s Drug Containment Solutions segment grew FY2025 revenue 11.9% at constant currencies to EUR 548.0 million, with segment EBITDA up 34.9% to EUR 127.5 million, a 23.5% margin, against group revenue of EUR 986.2 million, up 5.8% cc. Growth was concentrated in sterile ready-to-use cartridges and vials and specialty vials for biologic drugs, outpacing the group average by a wide margin. Parenteral fillers and biologics manufacturers are the primary buyers, driven by expanding injectable pipelines that demand higher-spec primary containment than standard vials provide. This concentrates incremental packaging value in sterile, ready-to-use containment formats rather than across the broader pharmaceutical packaging base.

Growth Drivers and Restraints

Pharmaceutical packaging demand is being pulled forward by injectable-drug volume and held back by a widening compliance and tariff cost base, netting to an 8.73% CAGR to USD 367.88 Billion by 2035.

GLP-1 and biologic injectable volume is pulling primary-containment capacity into Asia Pacific

SCHOTT AG reported FY2024 sales of EUR 2.8 billion across 17,400 employees and cited a projected 33% CAGR for the GLP-1 segment as the basis for adding syringe and cartridge glass-tubing production in India, announced 8 August 2025. The mechanism runs from injectable prescription growth through fill-finish contract manufacturers to upstream tubing melters: each new GLP-1 or biologic launch requires qualified Type I borosilicate tubing before a single pen or vial can be filled, so capacity decisions trail molecule approvals by design. Asia Pacific absorbs the resulting investment first, since new tubing lines are being sited close to India- and China-based fill-finish capacity rather than shipped as converted glass from Europe.

India’s recycled-content mandate is reformulating secondary and tertiary pharmaceutical packs

India’s Plastic Waste Management (Amendment) Rules, 2026, notified 31 March 2026 by the Ministry of Environment, Forest and Climate Change, raise recycled-content floors on the plastic component of rigid, flexible and multi-layered packaging to 30%, 10% and 5% for the 2025-26 compliance year, stepping up to 60%, 20% and 10% by 2028-29. Aseptic cartons and blister overwraps sit in the multi-layered category, so the obligation transmits to secondary and tertiary converters rather than primary vials or blister films. Brand owners selling into India must requalify carton board and laminate suppliers against the phased targets, opening a multi-year reformulation cycle that converters with existing recycled-content supply lines are positioned to capture.

China’s 2025 Pharmacopoeia and the EU’s ePI programme are raising the qualification bar

China’s National Medical Products Administration and National Health Commission, in Announcement No. 29 of 2025, introduced the country’s first systematic packaging-material standard framework – one general chapter plus four material-specific guidelines for glass, rubber, plastic and metal – effective 1 October 2025, superseding the 2020 Pharmacopoeia and 2015 YBB standards. In parallel, the European Medicines Agency’s Electronic Product Information programme is pushing digital labelling and traceability data onto secondary packaging. Both regimes move qualification testing and artwork development earlier in the development cycle, favouring converters and material suppliers already running full life-cycle documentation over single-variety compliance.

PPWR’s recycled-content mandate stops at the secondary pack, not the vial

Regulation (EU) 2025/40 excludes immediate packaging defined under Directive 2001/83/EC and Regulation (EU) 2019/6, plus contact-sensitive plastic packaging for medical devices under Regulations (EU) 2017/745 and 2017/746, from minimum recycled-content obligations, with the exemption due for review only in 2035. Recycled-content targets bind cartons, shrink film and outer trays; glass vials, COP/COC syringes and primary blister film stay on virgin substrate. The mechanism caps the addressable recycled-content opportunity at the lower-margin secondary tier – carton and corrugate converters capture the compliance-driven design work, while primary-containment glass and polymer suppliers face no near-term substrate-switching mandate to sell against.

Customer concentration and new US tariffs are compressing containment-supplier margins

SCHOTT Pharma’s Drug Delivery Systems segment posted FY2025 revenue of EUR 438.8 million, down 1.3% at constant currencies, after a key customer revised its glass-syringe demand outlook for FY2026 on 11 December 2025. Gerresheimer cut full-year guidance twice in 2025, moving from 3%-5% organic growth and a 22% adjusted EBITDA margin to -4% to -2% organic revenue and an 18.5%-19% margin by 9 October, citing weak Moulded Glass and oral-liquid plastic containment demand. US Section 232 measures add a 100% default tariff on patented pharmaceutical articles from 31 July 2026, raising landed cost on imported containment components into the largest single national buyer market.

Segment Analysis

By Product

• Primary (largest, 77% share) – Packaging that directly contacts the drug product, such as blister packs, vials, ampoules, and bottles, providing the immediate barrier and dosage containment
• Bottles

• Plastic Bottles
• Glass Bottles
• Blister Packs

• PVC Blister Packs
• Alu-Alu Blister Packs
• Cold Form Blister Packs
• Vials & Ampoules

• Vials
• Ampoules

• Prefilled Syringes
• Pouches & Sachets
• Secondary (fastest-growing) – Outer packaging that groups and protects primary packs during handling and distribution, such as cartons, folding boxes, and shrink-wrap bundles
• Cartons

• Folding Cartons
• Corrugated Cartons
• Labels
• Tertiary – Bulk shipping packaging such as corrugated cases and pallets used to consolidate secondary packs for transport and warehouse storage

• Corrugated Boxes
• Shrink Wraps
• Pallets

Primary packaging held 77% of the Pharmaceutical Packaging Market in 2025, the dominant share among the three product tiers. Primary formats sit in direct contact with the drug product, so extractables-and-leachables testing, formulation stability data, and regulatory dossier filings anchor purchasing decisions around the incumbent bottle, blister, vial, or syringe format rather than switching on price. Reformulating a primary pack requires re-qualification with the relevant health authority, which locks in supplier relationships for the life of a drug’s approval. Secondary packaging is set to expand at the fastest pace among the three tiers. Serialization mandates under track-and-trace regulations and unit-dose carton formats for hospital and mail-order pharmacy are pulling carton and label volume ahead of bulk tertiary shipping formats.

By Material

• Plastics & Polymers (largest) – Synthetic materials such as PET, PP, and PVC molded into bottles, blister packs, vials, and caps that contain and protect drug products
• Polyethylene (PE)

• HDPE
• LDPE

• Polypropylene (PP)
• Polyethylene Terephthalate (PET)
• Polyvinyl Chloride (PVC)
• Polystyrene (PS)
• Glass – A rigid, chemically inert material made from fused silica, formed into vials, ampoules, and syringes for injectable and sensitive formulations

• Type I (Borosilicate)
• Type II
• Type III
• Paper & Paperboard (fastest-growing) – Cellulose-based material converted into cartons, labels, and inserts that hold dosage units and carry printed dosing and safety information

• Folding Cartons
• Corrugated Board
• Paper Labels
• Aluminum Foil – A thin, malleable metal sheet laminated onto film to form blister lidding and strip packs that seal individual tablet or capsule doses

• Blister Foil
• Strip Foil
• Wrapping Foil / Sachets
• Others – A grouping of additional materials, including rubber, elastomers, and metal alloys, used for closures, stoppers, and specialty packaging components

Plastics and polymers lead the Pharmaceutical Packaging Market by material, ahead of glass, paper and paperboard, aluminum foil, and other substrates. Polyethylene, polypropylene, and PET mold into bottles, blister trays, and vial components at lower unit cost and lighter weight than glass, and their compatibility with high-speed blister and bottling lines keeps conversion costs down for high-volume solid-dose manufacturing. Paper and paperboard is growing fastest among the five material groups. Brand owners and regulators are pushing folding cartons and paper-based secondary packs to reduce plastic content in outer packaging, and PFAS-restriction pressure on food-contact-adjacent coatings is reinforcing the shift toward paper structures for cartons, labels, and inserts that do not touch the drug product directly.

By Application

• Pharmaceutical Manufacturing (largest) – Packaging performed by drug producers themselves to protect, contain, and label medicines during production and before distribution to supply chains
• Primary Packaging

• Blister Packs
• Bottles
• Vials and Ampoules
• Prefilled Syringes
• Sachets and Pouches
• Secondary Packaging

• Cartons
• Labels
• Inserts and Leaflets
• Tertiary Packaging

• Shrink Wrap
• Corrugated Boxes
• Pallets
• Retail Pharmacy – Packaging formats dispensed directly to consumers at drugstores, including prescription bottles, blister strips, and patient information inserts

• Prescription Dispensing Packs
• Over-the-Counter Packs
• Unit-Dose Packs
• Institutional Pharmacy – Packaging supplied to hospitals, nursing homes, and clinics, often in unit-dose or bulk formats suited to controlled multi-patient dispensing

• Unit-Dose Packaging
• Multi-Dose Packaging
• Emergency/Crash Cart Packaging
• Contract Packaging – Outsourced packaging services where third-party providers handle filling, labeling, and sealing of drug products on behalf of manufacturers

• Blister Packing Services
• Bottling Services
• Labeling and Serialization Services
• Cold Chain Packaging Services
• Others – Remaining application areas such as clinical trial supplies, veterinary medicines, and nutraceutical packaging not classified under the main categories

• Cosmeceuticals
• Nutraceuticals
• Veterinary
• Research & Laboratory Use

Pharmaceutical manufacturing accounts for the largest share of application demand, ahead of retail pharmacy, institutional pharmacy, contract packaging, and other uses. Drug producers integrate primary, secondary, and tertiary packaging directly into production lines to meet batch-release and labeling requirements before product reaches a distributor, concentrating purchasing power with manufacturers rather than downstream dispensers. Contract packaging is emerging as the structural growth channel within the application mix. Manufacturers are outsourcing blister packing, bottling, and serialization and labeling work to contract packaging organizations to manage compliance complexity and variable production runs, while cold-chain packaging services are expanding alongside the biologics and injectable pipeline that institutional and retail pharmacy channels ultimately dispense.

Regional Analysis

North America Held 39.0% of the Market on a Reshoring Investment Wave

North America held 39.0% of the pharmaceutical packaging market in 2025, equivalent to USD 62.123 Billion, ranked first on a manufacturing base anchored by major drugmakers. BD committed USD 110 Million on 13 January 2026 to expand prefillable syringe capacity at its Columbus, Nebraska plant – USD 100 Million for Neopak glass syringes in 1 mL and 2.25 mL formats, USD 10 Million for cannula lines – framed explicitly as reshoring for biologic and GLP-1 drug delivery, with supply from mid-2026.

How Is the EU Deforestation Regulation Delay Shaping European Converters?

The Council of the EU signed off a second postponement on 18 December 2025, pushing the Deforestation Regulation’s application to 30 December 2026 for large and medium operators and 30 June 2027 for micro and small ones, giving fibre-based pharmaceutical cartons and leaflets an extra year of due-diligence lead time. That relief lands on a research-based pharmaceutical sector that produced an estimated EUR 440 Billion of output in 2024, up from roughly EUR 390 Billion in 2023, with Germany’s packaging demand compounding at 7.9% and the UK’s at 7.6% through 2035.

Asia Pacific Is the Fastest-Growing Region, Led by China’s Revised Pharmacopoeia

Asia Pacific is the fastest-growing region in the market through 2035 – China’s packaging demand is compounding at 10.8% and India’s at 9.4%, ahead of South Korea’s 7.4% and Japan’s 7.2%. The 2025 edition of the Chinese Pharmacopoeia added 3 new guidelines and 42 test methods for packaging materials, forming a “1+4+58” standard covering glass, rubber, plastic and metal that retires the 2020 Pharmacopoeia and 2015 YBB series, putting suppliers selling into China through a requalification cycle.

Middle East & Africa Is Localizing Fill-Finish Capacity Behind Import-Substitution Policy

Saudi Arabia’s National Industrial Development and Logistics Program has pushed pharmaceutical manufacturers toward local fill-finish and packaging lines as an import-substitution priority, while Egypt’s state procurement channel anchors demand for a regional pharmaceutical sector still reliant on imported specialty films and closures. Neither a share nor a growth rate is established for the region; its packaging base remains tied to a handful of national manufacturing hubs rather than a broad converter footprint.

Latin America’s Packaging Base Concentrates Around Brazil and Mexico

Brazil’s health regulator, ANVISA, oversees the region’s largest domestic pharmaceutical manufacturing and packaging base, while Mexico’s proximity to the United States positions its converters to serve nearshored fill-finish lines feeding North American drug supply. Import dependence for specialty barrier films and closures persists across smaller Latin American markets, leaving regional packaging capacity concentrated in these two national industries rather than distributed evenly across the bloc.

Country Growth Comparison

Country	CAGR (2025-2035)
China	10.80%
India	9.40%
Germany	7.90%
United Kingdom	7.60%
South Korea	7.40%
Japan	7.20%

The six country CAGRs span 3.60 percentage points, from China at 10.80% to Japan at 7.20%. China’s rate is pulled up by the 2025 Chinese Pharmacopoeia’s “1+4+58” packaging-material standard system, which adds 42 test methods and forces converters supplying the Chinese market to requalify glass, rubber, plastic and metal packaging lines. India follows close behind on the scale of its generics export manufacturing base. Germany and the United Kingdom sit mid-table, growing off Europe’s roughly EUR 440 billion research-based pharmaceutical production value rather than new packaging-capacity buildout. South Korea and Japan anchor the bottom: both run mature, already well-packaged pharmaceutical manufacturing bases, so incremental packaging demand tracks routine drug volume growth rather than infrastructure expansion. The pattern places the top of the table with markets absorbing new compliance costs, and the bottom with markets where the packaging base is already built out.

Competitive Landscape

The Pharmaceutical Packaging Market is moderately consolidated, with a tier of established primary-packaging and drug-delivery specialists sitting alongside broader diversified packaging groups and paper-based converters serving secondary packaging.

Competition centers on qualification status with drug formulations, since switching a food-contact or pharma-grade material requires re-validation that brand owners are reluctant to repeat. Converting capability and line speed determine who can supply high-volume injectable and GLP-1 fill-finish programs, while barrier performance and sterile/ready-to-use formats separate specialists from generalists. Proximity to filling operations and co-development relationships with brand owners further shape share, particularly for glass vials, cartridges, and prefillable systems.

No single-source top-five share figure is available for this market. It is led by an established group of players spanning broad packaging groups – Amcor plc, Gerresheimer AG, SCHOTT Pharma – drug-delivery and containment specialists including West Pharmaceutical Services, Inc., AptarGroup, Inc., and Becton, Dickinson and Company, and scale participants such as Nipro Corporation, Catalent, Inc., and CCL Industries Inc., alongside Drug Plastics Group, Owens Illinois Inc., Berry Global, Inc., SGD S.A., WestRock Company, International Paper Company, COMAR LLC, and Vetter Pharma International.

Which strategic moves are reshaping capacity and portfolios?

Amcor expanded its Sira plant in Karnataka, India, in June 2026, adding an automated vision-inspection line for ophthalmic containers and injectable vials to shorten lead times. SCHOTT Pharma inaugurated an expanded vial facility in Lebanon, Pennsylvania, in June 2026, backed by BARDA funding, more than tripling local high-value capacity. Vetter Pharma announced a new aseptic filling site in Saarlouis, Germany, in January 2026, with construction beginning mid-2026. Nipro completed its acquisition of Croatian glass-container maker Piramida in March 2026, extending its European ampoule footprint.

Strategic Outlook

The clearest whitespace is sterile, ready-to-use primary containment for biologic and GLP-1 injectables. SCHOTT’s Drug Containment Solutions growth and BD’s committed Nebraska prefillable-syringe capacity show glass and polymer suppliers with qualified fill-finish lines capturing volume that legacy vial and ampoule capacity cannot absorb. Realizing this depends on suppliers holding investment through qualification cycles, since customer-side demand can reverse quickly, as SCHOTT’s own polymer-syringe segment found when a key customer’s outlook shifted.

By 2035, the market is projected to approach USD 367.88 Billion at an 8.73% CAGR, and structure bifurcates. Primary containment stays on virgin substrate under PPWR’s exemption, while secondary and tertiary pharmaceutical packaging absorbs recycled-content mandates and mono-material redesign. Buyers are expected to weight supply security and qualification cost above unit price when selecting containment partners, favoring suppliers that pair sterile fill-finish scale with demonstrated regional manufacturing resilience.

Pharmaceutical Packaging Market Report Scope

Attribute	Detail
Market Size 2025	159.29 (USD Billion)
Market Size 2026	173.62 (USD Billion)
Market Size 2035	367.88 (USD Billion)
Compound Annual Growth Rate (CAGR)	8.73% (2026 to 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Segment Analysis and Trends
Base Year	2025
Market Forecast Period	2026 – 2035
Historical Data	2020 – 2025
Market Forecast Units	USD Billion
Key Companies Profiled	Amcor plc; Gerresheimer AG; SCHOTT Pharma; West Pharmaceutical Services, Inc.; AptarGroup, Inc.; Becton, Dickinson and Company; Nipro Corporation; Catalent, Inc.; CCL Industries Inc.; Drug Plastics Group; Owens Illinois Inc.; Berry Global, Inc.
Segments Covered	By Product, By Material, By Application
Key Market Opportunities	Domestic prefillable-syringe and vial capacity for biologic and GLP-1 delivery is the clearest whitespace, as reshoring investment sidesteps Section 232 tariff exposure on imported containment.
Key Market Dynamics	Biologic and GLP-1 demand is bifurcating the market, lifting specialty containment such as ready-to-use vials while depressing demand for glass syringes and moulded-glass formats.
Regions Covered	North America, Europe, Asia Pacific, Middle East & Africa, Latin America

Market Insights

Frequently Asked Questions

Explore key insights into the Pharmaceutical Packaging Market, including market size, growth outlook, regional trends, leading segments, growth drivers, key players, and regulatory developments.

01 How big is the Pharmaceutical Packaging Market?

The Pharmaceutical Packaging Market was valued at USD 159.29 Billion in 2025, rising to an estimated USD 173.62 Billion in 2026. This scale reflects primary containment, secondary cartons and labels, and tertiary shipping formats across pharmaceutical manufacturing, retail pharmacy, institutional pharmacy, and contract packaging worldwide.

02 What is the growth forecast for the Pharmaceutical Packaging Market?

The market is projected to reach USD 367.88 Billion by 2035, expanding at a CAGR of 8.73% between 2025 and 2035. Growth compounds off a 2025 base of USD 159.29 Billion, more than doubling market value inside the decade as primary containment and biologic delivery formats scale.

03 Which region holds the largest share of the Pharmaceutical Packaging Market?

North America held 39.0% of the Pharmaceutical Packaging Market in 2025, the largest regional share. The lead rests on a dense pharmaceutical manufacturing base and the concentration of major drugmakers, with the United States alone accounting for USD 43.55 Billion of 2025 value.

04 Which region is growing fastest in the Pharmaceutical Packaging Market?

Asia Pacific is the fastest-growing region through 2035. Expansion tracks China’s 10.8% CAGR and India’s 9.4% CAGR to 2035, the two fastest national rates in the market, alongside broader healthcare-infrastructure build-out across the region.

05 Which segment leads the Pharmaceutical Packaging Market?

Primary packaging leads the Pharmaceutical Packaging Market with a 77% share by product type. Formats such as blister packs, vials, ampoules, prefilled syringes, and bottles provide the direct drug-contact barrier and dosage containment that secondary cartons and tertiary shipping cases only protect in transit.

06 What is driving growth in the Pharmaceutical Packaging Market?

Biologic and GLP-1 drug volumes are the primary growth driver, with SCHOTT Pharma’s containment segment growing 11.9% in FY2025 on demand for sterile vials and cartridges. Active US drug shortages are also pushing manufacturers to onshore fill-finish and primary packaging capacity.

07 Who are the key players in the Pharmaceutical Packaging Market?

Amcor, Gerresheimer, SCHOTT Pharma, and West Pharmaceutical Services lead alongside AptarGroup, Becton Dickinson, Nipro Corporation, and Catalent. These companies span broad packaging conglomerates and specialists in drug-delivery and containment systems, competing on pharma-contact qualification, recycled-content supply security, and converting capacity.

08 How is the EU Packaging and Packaging Waste Regulation affecting the Pharmaceutical Packaging Market?

Regulation (EU) 2025/40 exempts immediate drug-contact packaging from mandatory recycled-content targets, so primary containment stays on virgin substrate. Recycled-content obligations apply to secondary and tertiary pharmaceutical packaging such as cartons and shipping cases, with the primary-packaging exemption set for review by 2035.